Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf - What's Changed

Simply Wall St.03-05

In late February 2026, Ligand Pharmaceuticals reported a sharp improvement in fourth-quarter and full-year 2025 results, turning prior-year losses into net income of US$44.78 million for the quarter ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617676435?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-05 06:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617676435","market":"nz","top_or_hot":-1,"title":"Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>In late February 2026, Ligand Pharmaceuticals reported a sharp improvement in fourth-quarter and full-year 2025 results, turning prior-year losses into net income of US$44.78 million for the quarter ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-is-up-81-after-swinging-to-profi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLigand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-05 06:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-is-up-81-after-swinging-to-profi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late February 2026, Ligand Pharmaceuticals reported a sharp improvement in fourth-quarter and full-year 2025 results, turning prior-year losses into net income of US$44.78 million for the quarter ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-is-up-81-after-swinging-to-profi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EQR","symbol_name":"资产住宅公司","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-is-up-81-after-swinging-to-profi","article_id":"2617676435","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-is-up-81-after-swinging-to-profi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2617676435","pubTimestamp":1772663524,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late February 2026, Ligand Pharmaceuticals reported a sharp improvement in fourth-quarter and full-year 2025 results, turning prior-year losses into net income of US$44.78 million for the quarter and US$124.45 million for the year, while reiterating 2026 revenue guidance of US$245 million to US$285 million.\nAt the same time, the company moved to broaden its financing and capital-raising options by filing a US$100 million at-the-market common stock offering and an omnibus shelf...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"EQR":"资产住宅公司","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4215":"住宅房地产投资信托","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药","BK4551":"寇图资本持仓","BK4587":"ChatGPT概念","BK4588":"碎股","BK4528":"SaaS概念","LGND":"Ligand Pharmaceuticals Inc.","BK4585":"ETF&股票定投概念","BK4023":"应用软件","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4139":"生物科技","LU0566484027.USD":"安本美国小盘成长股","BK4543":"AI"},"translate_title":"Ligand Pharmaceuticals(LGND)在扭亏为盈并提交新股票搁置后上涨8.1%-发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":1.5,"EQR":1.5,"AIYY":0.6},"content_text":"In late February 2026, Ligand Pharmaceuticals reported a sharp improvement in fourth-quarter and full-year 2025 results, turning prior-year losses into net income of US$44.78 million for the quarter and US$124.45 million for the year, while reiterating 2026 revenue guidance of US$245 million to US$285 million. At the same time, the company moved to broaden its financing and capital-raising options by filing a US$100 million at-the-market common stock offering and an omnibus shelf registration covering common and preferred stock, debt securities, warrants and units. With this combination of stronger earnings and fresh capital flexibility, we’ll now examine how the news reshapes Ligand’s investment narrative. Find 49 companies with promising cash flow potential yet trading below their fair value.AdvertisementLigand Pharmaceuticals Investment Narrative RecapTo own Ligand today, you need to believe its asset light royalty model can keep translating partner drug progress into sustained cash generation, while managing concentrated product risk. The latest earnings rebound and reaffirmed 2026 guidance support confidence in near term royalty momentum, but the new US$100 million at the market program introduces incremental dilution risk that does not materially change the core catalyst around partner execution on key launches. The omnibus shelf registration filed alongside the at the market equity program is particularly relevant here, as it enlarges Ligand’s toolkit to fund acquisitions and external asset deals that expand its royalty base. For investors focused on upcoming product and royalty milestones, this broader financing capacity sits in the background, potentially enabling the company to lean further into the same acquisition driven model that underpins its current catalyst story. Yet beneath the stronger earnings and added capital flexibility, investors should still be aware of concentrated exposure to a handful of royalty assets such as... Read the full narrative on Ligand Pharmaceuticals (it's free!)Ligand Pharmaceuticals' narrative projects $315.6 million revenue and $121.1 million earnings by 2028. This requires 18.9% yearly revenue growth and a $197.0 million earnings increase from -$75.9 million today.Uncover how Ligand Pharmaceuticals' forecasts yield a $243.44 fair value, a 19% upside to its current price.Exploring Other PerspectivesLGND 1-Year Stock Price Chart Three fair value estimates from the Simply Wall St Community span a wide range between US$38.77 and US$279.18, underlining how far apart individual views can be. When you set those against the reliance on a concentrated royalty portfolio, it becomes even more important to compare several viewpoints before deciding how Ligand’s story fits into your own expectations.Explore 3 other fair value estimates on Ligand Pharmaceuticals - why the stock might be worth less than half the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Ligand Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Ligand Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ligand Pharmaceuticals' overall financial health at a glance.Want Some Alternatives?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617676435","isCrawlerRequest":true}